Scancell (LON:SCLP) Trading 5.1% Higher - Should You Buy?

Key Points

• Scancell Holdings plc's stock increased by 5.1% to GBX 10.25 ($0.14) after trading as high as GBX 10.50 ($0.14), with trading volume hitting approximately 9.9 million shares, a 953% increase from the average daily volume.
• The company has a market cap of £112.27 million, a PE ratio of -16.62, and a notably low debt-to-equity ratio of -566.79.
• Insider Martin Diggle purchased 44,944 shares at GBX 9 ($0.12) each, indicating confidence in the company's future prospects.

Scancell Holdings plc (LON:SCLP - Get Free Report) traded up 5.1% during mid-day trading on Friday . The company traded as high as GBX 10.50 ($0.14) and last traded at GBX 10.25 ($0.14). 9,863,690 shares were traded during trading, an increase of 953% from the average session volume of 936,871 shares. The stock had previously closed at GBX 9.75 ($0.13).

Scancell Trading Up 5.5%

The company has a debt-to-equity ratio of -566.79, a current ratio of 3.42 and a quick ratio of 13.01. The stock's fifty day simple moving average is GBX 9.93 and its 200-day simple moving average is GBX 9.44. The firm has a market cap of £120.14 million, a PE ratio of -17.78 and a beta of 0.35.

Insider Buying and Selling

In other news, insider Martin Diggle acquired 4,400,000 shares of the business's stock in a transaction on Friday, August 1st. The stock was bought at an average price of GBX 10 ($0.13) per share, for a total transaction of £440,000 ($584,795.32). 4.96% of the stock is owned by company insiders.

Scancell Company Profile

Scancell LSE: SCLP is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers. Scancell has developed a pipeline of ‘off-the-shelf' vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.